Current directions in the treatment of classical Hodgkin lymphoma

• Type of Material: Article
• Authors: Frank G. Keller, Emory University; Brad Kahl, Washington University, St. Louis; Jonathan W. Friedberg, University of Rochester
• Language: English
• Date: 2023-09-29
• Publisher: John Wiley and Sons Ltd.
• Publication Version: Final Published Version
• Copyright Statement: © 2023 The Authors
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): https://doi.org/10.1002/jha2.784
• Title of Journal or Parent Work: eJHaem
• Volume: 4
• Issue: 4
• Start Page: 908
• End Page: 911
• Grant/Funding Information: N/A
• Keywords: classical Hodgkin lymphoma; chemotherapy; treatment
• Research Categories: Health Sciences, Oncology; Health Sciences, Medicine and Surgery

Abstract

Optimal management of patients who present with Hodgkin lymphoma continues to evolve. Most patients are cured with current treatment strategies, some but both short and long‐term morbidity and mortality from treatment have particular relevance given the youth of the patient population. Combininations of targeted agents together with conventional chemotherapy have recently been investigated in phase 3 cliniial trials for advanced‐stage Hodkgkin lymphoma, and have demonstrated improved efficacy compared with chemotherapy alone. These include both antibody‐drug conjugates and PD‐1 blockade. Treatment approaches have historically differed between pediatric and adult groups, but recent collaborations between adullt and pediatric groups via the NCTN mechanism have resulted in the successful completion of enrollment in an advanced‐stage Hodgkin lymphoma and the opening of an early‐stage trial that will enroll patients accross a broad age spectrum. Novel approachs incorporating targeted and immunomodulatory agents in the relapse setting are being actively investagated in the relapse setting as well.